Terms: = Thyroid cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
37 results:
1. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
2. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
3. p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.
Bai F; Liu X; Zhang X; Mao Z; Wen H; Ma J; Pei XH
Cell Cycle; 2023 Jul; 22(13):1637-1653. PubMed ID: 37345432
[TBL] [Abstract] [Full Text] [Related]
4. Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects.
Elahi AH; Morales CS; Xu XL; Eliades A; Patsalis PC; Abramson DH; Jhanwar SC
Adv Biol Regul; 2023 May; 88():100964. PubMed ID: 37004354
[TBL] [Abstract] [Full Text] [Related]
5. Combined treatment with
Huang S; Cui M; Wang R; Yang G; Wang N; Cui L; Ma G
Nucleosides Nucleotides Nucleic Acids; 2023; 42(9):731-742. PubMed ID: 36924446
[TBL] [Abstract] [Full Text] [Related]
6. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
Sakai T
Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
[TBL] [Abstract] [Full Text] [Related]
7. ZFPM2-AS1: An Oncogenic Long Non-coding RNA in Multiple cancer Types.
Tan F
Mini Rev Med Chem; 2023; 23(1):88-98. PubMed ID: 35578882
[TBL] [Abstract] [Full Text] [Related]
8. Effects of
Orlandella FM; Mirabelli P; De Stefano AE; Iervolino PLC; Luciano N; D'Angelo S; Salvatore G
Oxid Med Cell Longev; 2022; 2022():6268755. PubMed ID: 35222800
[TBL] [Abstract] [Full Text] [Related]
9. Correlation and agreement between superb micro-vascular imaging and contrast-enhanced ultrasound for assessing radiofrequency ablation treatment of thyroid nodules: a preliminary study.
Lan Y; Li N; Song Q; Zhang MB; Luo YK; Zhang Y
BMC Med Imaging; 2021 Nov; 21(1):175. PubMed ID: 34809604
[TBL] [Abstract] [Full Text] [Related]
10. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for treatment Selection.
Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
[TBL] [Abstract] [Full Text] [Related]
11. PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
Putlyaeva LV; Demin DE; Uvarova AN; Zinevich LS; Prokofjeva MM; Gazizova GR; Shagimardanova EI; Schwartz AM
Biochemistry (Mosc); 2020 Jan; 85(1):108-118. PubMed ID: 32079522
[TBL] [Abstract] [Full Text] [Related]
12. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract] [Full Text] [Related]
13. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract] [Full Text] [Related]
14.
Jia D; Augert A; Kim DW; Eastwood E; Wu N; Ibrahim AH; Kim KB; Dunn CT; Pillai SPS; Gazdar AF; Bolouri H; Park KS; MacPherson D
Cancer Discov; 2018 Nov; 8(11):1422-1437. PubMed ID: 30181244
[No Abstract] [Full Text] [Related]
15. A Synergistic Anti-cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic thyroid cancer Cell Line and in a Mouse Xenograft Model.
Zhong WB; Tsai YC; Chin LH; Tseng JH; Tang LW; Horng S; Fan YC; Hsu SP
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932104
[TBL] [Abstract] [Full Text] [Related]
16. Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic thyroid cancer.
Chen MC; Tsai YC; Tseng JH; Liou JJ; Horng S; Wen HC; Fan YC; Zhong WB; Hsu SP
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236027
[TBL] [Abstract] [Full Text] [Related]
17. MONTE CARLO SIMULATION OF OUT-OF-FIELD ORGAN DOSES AND cancer RISK IN TANZANIA FOR RADIATION THERAPY OF UNILATERAL RETINOBLASTOMA USING A 60Co UNIT.
Suleiman SA; Qi Y; Pi Y; George Xu X
Radiat Prot Dosimetry; 2018 May; 179(3):263-270. PubMed ID: 29216393
[TBL] [Abstract] [Full Text] [Related]
18. Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Sawa A; Chiba T; Ishii J; Yamamoto H; Hara H; Kamma H
Endocr J; 2017 Nov; 64(11):1115-1123. PubMed ID: 28855436
[TBL] [Abstract] [Full Text] [Related]
19. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
[TBL] [Abstract] [Full Text] [Related]
20. Targeting MYC as a Therapeutic Intervention for Anaplastic thyroid cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract] [Full Text] [Related]
[Next]
